Leading global law firm Baker McKenzie has advised Sofinnova Partners (Sofinnova) and New Enterprise Associates (NEA) in an oversubscribed CHF 22.5 million Series A financing round of Polyneuron Pharamceuticals AG (Polyneuron). The round was led by Sofinnova and co-led by NEA, with the participation of existing investors.
Swiss start-up Polyneuron is a spin-off of the University of Basel. It researches the advancement of drugs derived from a glycopolymer platform. Sofinnova and NEA have come on board to help Polyneuron take its lead product into a first-in-human clinical trial. The compound, PN-1007, is a potential treatment for anti-MAG neuropathy, a rare nervous system disease.
Baker McKenzie Zurich provided advice to Sofinnova and NEA with regard to all legal and tax aspects of the Series A Financing Round. The Baker McKenzie team comprised Martin Frey (Partner), Philippine Dalla Corte (Associate), Susanne Liebel-Kotz (Associate) and Christian Rioult (Associate).
